Myasthenia gravis and neuromyelitis optica spectrum disorder A multicenter study of 16 patients
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
07/11/2013
07/11/2013
2012
|
Resumo |
Objective: To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody (AQP4-Ab)-mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and acetylcholine receptor antibody (AChR-Ab)-mediated myasthenia gravis (AChR-MG). Methods: The clinical details and antibody results of 16 patients with AChR-MG and AQP4-NMOSD were analyzed retrospectively. Results: All had early-onset AChR-MG, the majority with mild generalized disease, and a high proportion achieved remission. Fifteen were female; 11 were Caucasian. In 14/16, the MG preceded NMOSD (median interval: 16 years) and 11 of these had had a thymectomy although 1 only after NMOSD onset. In 4/5 patients tested, AQP4-Abs were detectable between 4 and 16 years prior to disease onset, including 2 patients with detectable AQP4-Abs prior to thymectomy. AChR-Abs decreased and the AQP4-Ab levels increased over time in concordance with the relevant disease. AChR-Abs were detectable at NMOSD onset in the one sample available from 1 of the 2 patients with NMOSD before MG. Conclusions: Although both conditions are rare, the association of MG and NMOSD occurs much more frequently than by chance and the MG appears to follow a benign course. AChR-Abs or AQP4-Abs may be present years before onset of the relevant disease and the antibody titers against AQP4 and AChR tend to change in opposite directions. Although most cases had MG prior to NMOSD onset, and had undergone thymectomy, NMOSD can occur first and in patients who have not had their thymus removed. Neurology (R) 2012;78:1601-1607 Ministry of Education, Culture, Sports, Science & Technology of Japan (MEXT) Ichiro Kanehara Foundation Merck-Serono UK Myasthenia Gravis Association, UK Novartis Teva Bayer Schering Pharma Biogen Idec Mitsubishi Chemical Medience Corporation Ministry of Education, Science and Technology of Japan Bayer-Schering Healthcare GW Pharma Merz SanofiAventis Medical Research Council of United Kingdom |
Identificador |
NEUROLOGY, PHILADELPHIA, v. 78, n. 20, pp. 1601-1607, MAY, 2012 0028-3878 http://www.producao.usp.br/handle/BDPI/43269 10.1212/WNL.0b013e31825644ff |
Idioma(s) |
eng |
Publicador |
LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA |
Relação |
NEUROLOGY |
Direitos |
closedAccess Copyright LIPPINCOTT WILLIAMS & WILKINS |
Palavras-Chave | #THYMIC MYOID CELLS #MULTIPLE-SCLEROSIS #WATER CHANNEL #THYMECTOMY #DISEASE #IMMUNOGLOBULIN #AUTOIMMUNITY #PATHOGENESIS #ANTIBODIES #DIAGNOSIS #CLINICAL NEUROLOGY |
Tipo |
article original article publishedVersion |